The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic solid tumors: a systematic review and meta-analysis - PubMed
3 hours ago
- #disitamab-vedotin
- #HER2
- #immunotherapy
- Combination of disitamab vedotin (DV) and immunotherapy shows promise for locally advanced or metastatic solid tumors.
- Systematic review and meta-analysis included 21 studies with 1183 patients.
- Pooled objective response rate (ORR) was 53%, disease control rate (DCR) was 82%, and median progression-free survival (mPFS) was 7.8 months.
- Superior efficacy observed in urothelial carcinoma, HER2-positive tumors, and first-line treatment settings.
- Treatment-related adverse events (TRAEs) occurred in 91.1% of patients (any-grade) and 36.8% (grade ≥3), with common side effects including fatigue, peripheral neuropathy, and hematological toxicities.
- Findings support further investigation in randomized controlled trials.